GREAT BRITAIN: Many are starting to hear about a marijuana-based pharmaceutical called Sativex. The drug, which comes as an oral spray, has already been approved in 24 countries as a treatment for multiple sclerosis.
While yet to be approved in the United States, Sativex is legally available in countries like Canada, Australia, Britain and, most recently, France. But the drug has generated a lot of talk in the U.S., largely due to its role in the medical marijuana debate.
According to a recent interview with GW Pharmaceuticals, the company behind the drug, Sativex could be just months away from FDA approval. And if that happens, there’s no doubt the debate over marijuana as a medicine will only intensify.